Atea Pharmaceuticals, Inc. 8-K

What Happened
Atea Pharmaceuticals, Inc. (AVIR) filed an 8‑K reporting the results of its 2026 Annual Meeting of Stockholders held June 18, 2026 (record date April 24, 2026). A total of 59,742,819 shares (about 74.65% of outstanding shares) were represented in person or by proxy. Broadridge Financial Solutions, Inc. certified the vote results. Three Class III directors — Jerome Adams, MD, MPH; Howard Berman, PhD; and Barbara Duncan — were elected to serve until the 2029 annual meeting. Shareholders also ratified KPMG LLP as the company’s independent registered public accounting firm for 2026 and approved, on an advisory (non-binding) basis, the compensation of the named executive officers.

Key Details

• Shares present/represented: 59,742,819 (≈74.65% of shares outstanding as of April 24, 2026).
• Director votes (FOR / WITHHOLD / Broker non‑vote):
  • Jerome Adams: 28,798,012 / 22,275,665 / 8,669,142
  • Howard Berman: 44,466,627 / 6,607,050 / 8,669,142
  • Barbara Duncan: 43,697,098 / 7,376,579 / 8,669,142
• Auditor ratification (Proposal 2): FOR 58,894,207; AGAINST 783,081; ABSTAIN 65,531; (Broker non‑vote 0).
• Advisory say‑on‑pay (Proposal 3): FOR 47,452,759; AGAINST 2,977,290; ABSTAIN 643,628; Broker non‑vote 8,669,142.

Why It Matters
These outcomes determine the company’s board composition and signal shareholder views on governance and executive pay. Electing the three Class III directors fills board seats through 2029. Ratifying KPMG keeps the current auditor in place for 2026, which affects financial reporting continuity. The advisory approval of executive compensation passed but with a meaningful number of against votes and broker non‑votes, which investors and the board may consider when reviewing pay practices and shareholder engagement.